Published in Proc Natl Acad Sci U S A on August 14, 2002
The ADAMTS metalloproteinases. Biochem J (2005) 3.95
Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest (2005) 2.50
ADAMTS10 mutations in autosomal recessive Weill-Marchesani syndrome. Am J Hum Genet (2004) 2.22
Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood (2012) 1.87
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood (2012) 1.73
The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem (2005) 1.73
Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol (2008) 1.69
Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci U S A (2009) 1.45
Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models. Blood (2015) 1.43
Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol (2010) 1.41
Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood (2013) 1.19
Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy? J Biol Chem (2005) 1.16
Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations. J Mol Model (2004) 1.15
Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost (2006) 1.15
Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress. J Biol Chem (2010) 1.09
Structure-function and regulation of ADAMTS-13 protease. J Thromb Haemost (2013) 1.06
Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost (2008) 1.02
Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. Pediatr Nephrol (2008) 1.01
Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol (2004) 1.00
Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. Semin Thromb Hemost (2005) 1.00
A new name in thrombosis, ADAMTS13. Proc Natl Acad Sci U S A (2002) 0.99
Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol (2007) 0.97
T cell immune abnormalities in immune thrombocytopenia. J Hematol Oncol (2014) 0.94
Extracellular Matrix Reorganization During Wound Healing and Its Impact on Abnormal Scarring. Adv Wound Care (New Rochelle) (2015) 0.91
Characterization of coding synonymous and non-synonymous variants in ADAMTS13 using ex vivo and in silico approaches. PLoS One (2012) 0.91
AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura. Blood (2013) 0.87
The kidney in thrombotic thrombocytopenic purpura. Minerva Med (2007) 0.85
Flow-driven assembly of VWF fibres and webs in in vitro microvessels. Nat Commun (2015) 0.84
Characterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage protease. PLoS One (2009) 0.83
N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity. Blood (2008) 0.82
Association of ADAMTS13 polymorphism with cerebral malaria. Malar J (2011) 0.82
The interaction between factor H and Von Willebrand factor. PLoS One (2013) 0.82
A shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpura. Transfusion (2011) 0.82
ADAMTS13 and microvascular thrombosis. Expert Rev Cardiovasc Ther (2006) 0.82
Detection of intracellular ADAMTS13, a secreted zinc-metalloprotease, via flow cytometry. Cytometry A (2009) 0.81
ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy. Diabetes (2013) 0.81
ADAMTS13 gene mutations in children with hemolytic uremic syndrome. Yonsei Med J (2011) 0.81
Production, crystallization and preliminary crystallographic analysis of an exosite-containing fragment of human von Willebrand factor-cleaving proteinase ADAMTS13. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.80
Thrombotic microangiopathy-like disorder after living-donor liver transplantation: a single-center experience in Japan. World J Gastroenterol (2011) 0.80
Frequency of Pro475Ser polymorphism of ADAMTS13 gene and its association with ADAMTS-13 activity in the Korean population. Yonsei Med J (2008) 0.80
Congenital thrombotic thrombocytopenic purpura associated with unilateral moyamoya disease. Pediatr Nephrol (2008) 0.79
Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura. Pediatr Nephrol (2008) 0.79
Inherited thrombotic thrombocytopenic purpura. Haematologica (2009) 0.79
Pathophysiology of Pediatric Multiple Organ Dysfunction Syndrome. Pediatr Crit Care Med (2017) 0.78
Proteolytic processing of von Willebrand factor by adamts13 and leukocyte proteases. Mediterr J Hematol Infect Dis (2013) 0.77
ADAMTS13 and von Willebrand factor interactions. Curr Opin Hematol (2015) 0.77
Biological functions of fucose in mammals. Glycobiology (2017) 0.76
A first bout of thrombotic thrombocytopenic purpura triggered by herpes simplex infection in a 45-year-old nulliparous female with Upshaw-Schulman syndrome. Blood Transfus (2013) 0.76
ADAM and ADAMTS Family Proteins and Snake Venom Metalloproteinases: A Structural Overview. Toxins (Basel) (2016) 0.76
ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies. Rambam Maimonides Med J (2014) 0.76
A Unique Case Involving a Female Patient with Upshaw-Schulman Syndrome: Low Titers of Antibodies against ADAMTS13 prior to Pregnancy Disappeared after Successful Delivery. Transfus Med Hemother (2014) 0.75
Why Do We Need ADAMTS13? Nihon Kessen Shiketsu Gakkai shi (2005) 0.75
Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis. Int J Hepatol (2011) 0.75
Candidate gene analysis using genomic quantitative PCR: identification of ADAMTS13 large deletions in two patients with Upshaw-Schulman syndrome. Mol Genet Genomic Med (2014) 0.75
Current status in diagnosis and treatment of hereditary thrombotic thrombocytopenic purpura. Hereditary Genet (2014) 0.75
Cyclosporin A impairs the secretion and activity of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat). J Biol Chem (2012) 0.75
Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene (1991) 38.64
Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature (2001) 6.95
Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem (1998) 6.14
Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood (1996) 3.39
Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood (1996) 3.36
The CUB domain. A widespread module in developmentally regulated proteins. J Mol Biol (1993) 3.08
Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem (2001) 3.02
Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A (1990) 2.23
Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood (1994) 2.12
Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood (1997) 2.12
Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood (2001) 1.92
Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol (2001) 1.71
A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem (2001) 1.67
ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases. General features and genomic distribution of the ADAM-TS family. J Biol Chem (1999) 1.53
Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol (2001) 1.50
Cloning and characterization of ADAMTS-14, a novel ADAMTS displaying high homology with ADAMTS-2 and ADAMTS-3. J Biol Chem (2001) 1.49
von Willebrand factor. J Clin Invest (1997) 1.37
Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood (2001) 1.37
Von Willebrand factor: molecular size and functional activity. Ann Hematol (1996) 1.26
Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size. Br J Haematol (1989) 1.18
Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse: frequency, pathogenesis, and meaning. Semin Hematol (1997) 1.10
Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol (2001) 1.05
ADAMTS: a novel family of proteases with an ADAM protease domain and thrombospondin 1 repeats. FEBS Lett (1999) 1.04
Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion (2002) 1.03
Localization of a collagen-interactive domain of human von Willebrand factor between amino acid residues Gly 911 and Glu 1,365. Blood (1987) 0.94
Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. Int J Hematol (2002) 0.92
Ticlopidine-Associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity. Int J Hematol (2001) 0.87
Plasma of patients with Upshaw-Schulman syndrome, a congenital deficiency of von Willebrand factor-cleaving protease activity, enhances the aggregation of normal platelets under high shear stress. Br J Haematol (2001) 0.85
Thrombotic thrombocytopenic purpura: a paradigm shift? Thromb Haemost (2000) 0.83
Pathophysiology and treatment of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS). Int J Hematol (2000) 0.83
Clopidogrel and side effects. Cardiology (2001) 0.80
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res (2009) 5.24
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res (2014) 4.83
Renal resistive index and cardiovascular and renal outcomes in essential hypertension. Hypertension (2012) 3.15
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol (2005) 2.86
Comparison between carotid-femoral and brachial-ankle pulse wave velocity as measures of arterial stiffness. J Hypertens (2009) 2.62
Glucose down-regulates Per1 and Per2 mRNA levels and induces circadian gene expression in cultured Rat-1 fibroblasts. J Biol Chem (2002) 2.30
The Japanese Society of Hypertension Guidelines for Self-monitoring of Blood Pressure at Home (Second Edition). Hypertens Res (2012) 2.23
ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood (2003) 2.06
Pulmonary venous flow and risk of cardiovascular disease in essential hypertension. J Hypertens (2008) 2.05
Vitamin E decreases bone mass by stimulating osteoclast fusion. Nat Med (2012) 2.04
[Juvenile neuronal ceroid-lipofuscinosis with hypertrophic cardiomyopathy and left ventricular noncompaction: a case report]. Rinsho Shinkeigaku (2014) 2.00
Autopsy case of sudden maternal death from thrombotic thrombocytopenic purpura. J Obstet Gynaecol Res (2012) 1.96
Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol (2009) 1.95
Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program (2004) 1.94
The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. Blood (2008) 1.93
Greater oxidative stress in healthy young men compared with premenopausal women. Arterioscler Thromb Vasc Biol (2002) 1.93
ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood (2009) 1.89
Localization of ADAMTS13 to the stellate cells of human liver. Blood (2005) 1.85
Genetic variations of regulator of G-protein signaling 2 in hypertensive patients and in the general population. J Hypertens (2005) 1.84
Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res (2006) 1.78
Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst (2012) 1.76
Impaired postural cerebral hemodynamics in young patients with chronic fatigue with and without orthostatic intolerance. J Pediatr (2002) 1.70
The endothelial antigen ESAM marks primitive hematopoietic progenitors throughout life in mice. Blood (2008) 1.63
Diagnostic accuracy of the 13C-urea breath test for childhood Helicobacter pylori infection: a multicenter Japanese study. Am J Gastroenterol (2002) 1.60
SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection. Blood (2002) 1.59
The Satb1 protein directs hematopoietic stem cell differentiation toward lymphoid lineages. Immunity (2013) 1.58
VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood (2003) 1.55
Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B. Atherosclerosis (2011) 1.55
Isoflurane protects renal function against ischemia and reperfusion through inhibition of protein kinases, JNK and ERK. Anesth Analg (2005) 1.54
Inhibitory effect of C-type natriuretic peptide (CNP) on cultured cardiac myocyte hypertrophy: interference between CNP and endothelin-1 signaling pathways. Endocrinology (2004) 1.53
Ndrg1-deficient mice exhibit a progressive demyelinating disorder of peripheral nerves. Mol Cell Biol (2004) 1.53
Masked hypertension and target organ damage in treated hypertensive patients. Am J Hypertens (2006) 1.52
The prevalence of Helicobacter pylori in Japanese children with gastritis or peptic ulcer disease. J Gastroenterol (2004) 1.50
Pulse pressure is an independent predictor for the progression of aortic wall calcification in patients with controlled hyperlipidemia. Hypertension (2004) 1.50
Cross-sectional characterization of all classes of antihypertensives in terms of central blood pressure in Japanese hypertensive patients. Am J Hypertens (2009) 1.50
Comparison of the active standing test and head-up tilt test for diagnosis of syncope in childhood and adolescence. Clin Auton Res (2004) 1.47
Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int (2010) 1.46
Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Am J Hypertens (2008) 1.46
Risk Stratification of Acute Kidney Injury Using the Blood Urea Nitrogen/Creatinine Ratio in Patients With Acute Decompensated Heart Failure. Circ J (2015) 1.46
Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci U S A (2009) 1.45
Low-dose vasopressin infusion therapy for refractory hypotension in ELBW infants. Pediatr Int (2009) 1.45
Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost (2008) 1.45
The effects of chymase on matrix metalloproteinase-2 activation in neointimal hyperplasia after balloon injury in dogs. Hypertens Res (2007) 1.45
High-density association study and nomination of susceptibility genes for hypertension in the Japanese National Project. Hum Mol Genet (2007) 1.44
Intravenous gamma globulin for thrombotic microangiopathy of unknown etiology. Pediatr Nephrol (2006) 1.43
Influence of adrenomedullin 2/intermedin gene polymorphism on blood pressure, renal function and silent cerebrovascular lesions in Japanese: the Ohasama study. Hypertens Res (2011) 1.43
Impact of RGS2 deficiency on the therapeutic effect of telmisartan in angiotensin II-induced aortic aneurysm. Hypertens Res (2010) 1.43
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res (2006) 1.43
Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology (2003) 1.40
Serial changes in renal function as a prognostic indicator in advanced heart failure patients with left ventricular assist system. Ann Thorac Surg (2012) 1.39
Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood (2005) 1.39
[Case of thrombotic thrombocytopenic purpura associated with clopidogrel]. Rinsho Shinkeigaku (2007) 1.37
Identification of strain-specific variants of mouse Adamts13 gene encoding von Willebrand factor-cleaving protease. J Biol Chem (2004) 1.35
Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost (2009) 1.33
Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol (2006) 1.30
Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci (2011) 1.30
Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun (2004) 1.29
Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion (2006) 1.28
Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008. Intern Med (2010) 1.27
Common variants in the ATP2B1 gene are associated with susceptibility to hypertension: the Japanese Millennium Genome Project. Hypertension (2010) 1.26
Japanese society of hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res (2003) 1.25
Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation (2008) 1.23
Nepmucin, a novel HEV sialomucin, mediates L-selectin-dependent lymphocyte rolling and promotes lymphocyte adhesion under flow. J Exp Med (2006) 1.21
Age-specific differences in outcomes after out-of-hospital cardiac arrests. Pediatrics (2011) 1.20
Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis (2004) 1.20
Impact of high-normal blood pressure on the risk of cardiovascular disease in a Japanese urban cohort: the Suita study. Hypertension (2008) 1.20
Differential expression patterns of NDRG family proteins in the central nervous system. J Histochem Cytochem (2007) 1.18
Loss of ACE2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice. Diabetes (2012) 1.17
Choroidal excavation with polypoidal choroidal vasculopathy: a case report. Clin Ophthalmol (2012) 1.16
Hypoxia-inducible factor-3alpha functions as an accelerator of 3T3-L1 adipose differentiation. Biol Pharm Bull (2009) 1.14
Acute renal failure due to obstructive urate stones associated with norovirus gastroenteritis. Pediatr Nephrol (2010) 1.14
The impact of visit-to-visit variability in blood pressure on renal function. Hypertens Res (2011) 1.13
Randomized controlled trial of magnesium sulfate infusion for severe birth asphyxia. Pediatr Int (2002) 1.12
Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens (2010) 1.11